2. PATIENT PROFILE
• NAME :Mahesh
AGE :22Years
SEX :MALE
WARD :GMMW
ADMISSION DATE :08-11-19
3. OBJECTIVES
CHIEF COMPLAINTS:-
Fever since 1 week
Joint pain since 1 week
HISTORY OF PRESENT ILLNESS:-
• H/O fever
High grade with chills
• H/O joint pains with swellings
• No cough
• No rashes
7. POLYARTHRITIS
Polyarthritis is any type of arthritis that involve 5 or more
joints is usually associated with auto-immune conditions and
may be experienced at any age.
Polyarthritis can present as acute episodes or it may be
chronic, lasting for more than 6 weeks.
Polyarthritis can follow many viral infections. It may evolve
into a specific type of auto-immune diseases , such as
rheumatoid arthritis, lupus.
8.
9. JOINTS
A joint is a point where 2 or more bones meet. There are 3
main types of joints.
1. Fibrous(immoveable)
2. Cartilaginous(partially movable)
3. Synovial(freely movable)
10.
11. CAUSES OF POLYARTHRITIS
There are many different causes of polyarthritis such as:-
Cancer
Gout
Sarcoidosis
Lupus
Rheumatoid arthritis
Chikungunya
Parovirus
13. DAILY VITALS
S.NO SYSTEMS DAY 1 DAY 2 DAY 3 DAY 4
1 BP(mm Hg) 110/70 100/60 120/80 120/70
2 PR 82bpm 78bpm 80bpm 74bpm
3 Rs Clear B/A
Crept
Clear Clear
14. DRUG CHART
S.NO DRUG
NAME
CATEGOR
Y
R.O.A DOSE
DAY
1
DAY 2 DAY 3
DAY 4
1 Inj.Artesi
nate
Anti-
malarial
IV 120mg √ √ √ √
2 Inj.Ceftri
axone
Anti-biotic IV 1gm √ √ √ √
3 Cap.doxy
cycline
Anti-biotic --
-
100mg √ √ √ √
4 Inj.panto
p
Anti-ulcer IV 40mg √ √ √ √
5 Tab.parac
etamol
NSAITS
Oral
500mg √ √ √ √
6
7
IVF
Tab.B-
complex
--- --- 2 NS
2 DNS
√ √ √ √
15. NON-PHARMACOLOGICAL
TREATMENT
•In general, people with arthritis should be advised to maintain
an ideal body weight and adhere to a balanced diet containing
adequate amounts of protein, fat, vitamins, and minerals and if
the patient’s body mass indexes greater than 30 they should be
advised to lose weight.
16. DRUG INTERACTIONS
• Between Doxycycline and Ceftriaxone ,
doxycycline decreases the effect of ceftriaxone
by pharmacodynamics antagonism .
Bacteriostatic agents inhibit the
effects of bacterial agents.